No abstract available
MeSH terms
-
Antineoplastic Agents / administration & dosage*
-
Benzamides
-
Drug Administration Schedule
-
Fusion Proteins, bcr-abl / antagonists & inhibitors*
-
Fusion Proteins, bcr-abl / genetics
-
Gene Expression Regulation, Leukemic
-
Humans
-
Imatinib Mesylate
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
-
Piperazines / administration & dosage
-
Protein Kinase Inhibitors / administration & dosage*
-
Pyrimidines / administration & dosage
-
Recurrence
-
Remission Induction
-
Survival Rate
-
Time Factors
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Benzamides
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyrimidines
-
abl-bcr fusion protein, human
-
Imatinib Mesylate
-
Fusion Proteins, bcr-abl